Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

Bibliographical data

Translated title of the contribution	Isatuximab, Carfilzomib, Lenalidomid und Dexamethason (Isa-KRd) in der Erstlinientherapie des Hochrisiko Multiplen Myeloms: Interimanalyse der GMMG-CONCEPT Studie
Original language	English
ISSN	0887-6924
DOIs	https://doi.org/10.1038/s41375-021-01431-x
Publication status	Published - 03.2022